A Prospective, Open-Label, Single-Arm Pilot Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
Latest Information Update: 28 Mar 2024
At a glance
- Drugs Bevacizumab (Primary) ; Sulfur hexafluoride (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 28 Mar 2024 New trial record